Category - Feature

Feature

SeaStar Medical prepares for FDA approval of device targeting treatment of pediatric acute kidney injury

SeaStar Medical (NASDAQ: ICU) expects an FDA Approval Order in the coming months for the company's Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) under a humanitarian device exemption (HDE).

October 31, 2023

Feature

Hygieia – leveraging science + research + technology to revolutionize how patients manage insulin dosing

Closely-held Hygieia, a digital therapeutics company for insulin therapy, is reforming how physicians and people with type 2 diabetes manage insulin with its breakthrough proprietary mobile app, d-Nav, which...

October 24, 2023

Feature

Jeeva Informatics’ software platform helping to increase clinical trial efficiency, accessibility

Closely-held Jeeva Informatics has developed a centralized electronic clinical platform that aims to help clinical trial sponsors increase the efficiency of their clinical trials, while expanding trial access to...

October 17, 2023

Feature

EndoGlow – advancing fluorescent-guided surgeries with breakthrough device and technology

Closely-held EndoGlow, a medical device company, is revolutionizing minimally invasive surgery and improving patient outcomes by enhancing visualization through its proprietary Tissue Reveal Technology (TRT), a polymer...

October 10, 2023

Feature

Inbound Health enabling in-home hospital-level care

Closely-held Inbound Health is enabling its health system partners to provide hospital and skilled nursing facility (SNF)-level care to patients in the comfort of their own home.

October 3, 2023

Feature

Korro Bio merger and financing to fuel RNA editing technology

Korro Bio’s reverse merger with Frequency Therapeutics (NASDAQ:FREQ), which is expected to close in the 2023 fourth quarter, and concurrent financing are expected to build up an investor base to bankroll Korro’s...

September 26, 2023

Feature

MIRA advancing marijuana 2.0 for anxiety, cognitive decline, pain in seniors

MIRA Pharmaceuticals (NASDAQ:MIRA) is developing MIRA1a, a novel synthetic analog of THC (tetrahydrocannabinol) to treat anxiety and cognitive decline in the elderly and neuropathic pain, with a lower impurity profile...

September 19, 2023

Feature

Avenue Therapeutics focused on 3 near-term assets for neurologic diseases

Avenue Therapeutics (NASDAQ:ATXI) has taken a quantum leap into the CNS space during landscape over the past 12 months by adding two early-stage clinical assets to its pipeline to complement its late-stage intravenous...

September 12, 2023

Feature

Glyscend pioneering new class of GI-targeted therapy for T2D and obesity

Closely-held Glyscend Therapeutics is developing an orally administered, gut-restricted drug for Type 2 diabetes and obesity, based on “duodenal exclusion” physiology, a key mechanism of gastric bypass surgery.

September 5, 2023

Feature

Convergent readies IND for next-gen targeted radiotherapy

Closely-held Convergent Therapeutics is rapidly advancing a next generation alpha-emitting prostate-specific membrane antigen (PSMA)-targeted radioantibody for an IND filing in October.

August 29, 2023

Category - Feature

SeaStar Medical prepares for FDA approval of device targeting treatment of pediatric acute kidney injury

Hygieia – leveraging science + research + technology to revolutionize how patients manage insulin dosing

Jeeva Informatics’ software platform helping to increase clinical trial efficiency, accessibility

EndoGlow – advancing fluorescent-guided surgeries with breakthrough device and technology

Inbound Health enabling in-home hospital-level care

Korro Bio merger and financing to fuel RNA editing technology

MIRA advancing marijuana 2.0 for anxiety, cognitive decline, pain in seniors

Avenue Therapeutics focused on 3 near-term assets for neurologic diseases

Glyscend pioneering new class of GI-targeted therapy for T2D and obesity

Convergent readies IND for next-gen targeted radiotherapy

General

More